Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use in hospitals


Clinical Benefit


The actual benefit of Cubicin is substantial.

Clinical Added Value

no clinical added value
According to the available data, it has not been demonstrated that Cubicin provides an improvement in actual benefit compared with the treatments used in the current management of complicated infections of the skin and soft tissues (IAB V).
However, it constitutes an additional treatment for the management of those infections

Contact Us

Évaluation des médicaments
All our publications